GPU vs ALT: Gastric Pull up Versus Free Flap Reconstruction for Laryngo-pharyngeal Defects

Sponsor
University of British Columbia (Other)
Overall Status
Recruiting
CT.gov ID
NCT03171558
Collaborator
(none)
20
1
2
71.5
0.3

Study Details

Study Description

Brief Summary

This study will compare the gastric pull up (GPU) with the free flap [(specifically, anterolateral thigh (ALT) and radial forearm free flap (RFFF)] techniques used in the reconstruction of alimentary tracts in patients who require laryngectomy and circumferential pharyngectomy for carcinoma resection. These two interventions will be compared by block randomizing 20 patients based on history of failed chemoradiation to undergo either ALT or RFFF. The primary outcome will be the type and number of postoperative complications. The secondary outcomes will include swallowing function, speech, and quality of life measures along with cancer specific endpoints.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Gastric Pull Up
  • Procedure: Free Flap Surgery
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Gastric Pull up Versus Free Flaps Reconstruction (Anterolateral Thigh and Radial Forearm Free Flap) for Laryngo-pharyngeal Defects: A Prospective Randomized Trial
Actual Study Start Date :
Mar 16, 2017
Anticipated Primary Completion Date :
Mar 1, 2022
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Gastric Pull Up

Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.

Procedure: Gastric Pull Up
Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.

Active Comparator: Free Flap

Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.

Procedure: Free Flap Surgery
Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
Other Names:
  • Anterolateral thigh free flap and radial forearm free flap
  • Outcome Measures

    Primary Outcome Measures

    1. Type and number of postoperative complications [Within 90 days of surgery occurring on the same or separate admission.]

      Complications will be divided by: (1) in-hospital mortality (2) reconstruction related complications (anastomotic leak, fistula formation, flap necrosis, flap stenosis or stricture, requirement for surgical revision), and (3) addition in-hospital complications ( bleeding, pulmonary, cardiac, infectious, abdominal, wound concern)

    Secondary Outcome Measures

    1. Surgical Time [Initial Surgery]

      Time from first incision to the end of surgical closure as documented on the nursing record.

    2. Operative blood loss [Initial surgery]

      Total volume of blood lost and accounted for in suction canisters as documented in nursing charts. (this excludes blood not accounted for in the suction containers)

    3. Operative Parameters [During initial surgery and within the first 72 hours.]

      Requirement for transfusion, measured in units of blood.

    4. Flap Donor Site Morbidity (RFFF) ) [Measure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (8 visits total)]

      Donor site associated quality of life (Toronto Extremity Salvage Score - Upper Extremity)

    5. Flap Donor Site Morbidity (ALT) [Measure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (8 visits total)]

      Donor site associated quality of life (Toronto Extremity Salvage Score - Lower Extremity)

    6. Time to return to swallowing [If occurs in hospital will be documented by the treating team. Otherwise will be documented based on patient or speech language pathology reporting at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)]

      Time from surgery to swallowing liquids.

    7. Time to return of FULL oral diet [Measure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)]

      Time from surgery to return of diet that is sufficient for patient to maintain nutrition without requiring G-tube or NG feeding. Patient or Speech Language Pathology reported.

    8. Requirement for feeding tube at 1 year after surgery. [Documented at 1 year follow up visit.]

      Whether patients are still feeding tube dependent for nutrition at 1 year follow up.

    9. Voice Function [Measure documented at time of surgical booking and at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)]

      Measured by Voice Handicap Index -10

    10. Dysphagia [Measure documented at time of surgical booking and at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)]

      M.D. Anderson Dysphagia Inventory for assessment of dysphagia

    11. Dumping Symptoms [Measure documented at time of surgical booking and at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (9 visits total)]

      Assessed with the dumping symptom rating scale

    12. Quality of Life [Measure documented at 1, 3, 6 and 12 months post-surgery, thereafter yearly for 5 years. (8 visits total)]

      Measure with combined scores of two questionnaires: European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ) - C30 and EORTC QLQ - H&N35

    13. Margin status of the resected specimen as reported by pathology [At the time of surgery]

      Will be classified as positive and negative based on what is reported at Vancouver General Hospital Pathology reports generated at the time of surgery. A measure of clearance in millimeters will also be provided.

    14. Time to progression [Patients will be monitored for 5 years post-operatively]

      time from the date of the surgery until local, regional, or metastatic disease is detected

    15. Disease Free Survival [Patients will be monitored for 5 years post-operatively]

      Time from the date of the surgery until a patient experiences a recurrence, a new primary cancer or death

    16. Progression-free survival [Patients will be monitored for 5 years post-operatively]

      Time from the date of the surgery until a patient shows sign of disease progression

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Willing to provide informed consent, attend follow-up visits and complete questionnaires

    • Have an Eastern Cooperation Oncology Group (ECOG) performance status of 0-2

    • Patients with carcinoma of thyroid, larynx, hypopharynx, or cervical esophagus requiring surgery as a primary treatment modality or after chemoradiation treatment failure

    • Laryngectomy and circumferential pharyngectomy as recommended by the head and neck tumor board

    Exclusion Criteria:
    • Serious medical co morbidities or other contraindications to surgery

    • Metastatic disease

    • Pregnant or lactating women

    • Patients whose clinical circumstances are such that one surgical intervention would be recommended over the other: The cancer extends into the the thorax as seen on pre-operative CT scan. In these patients, the GPU reconstruction is preferred.

    • Patients who have liver cirrhosis or multiple previous surgeries on the stomach would not be candidates for the GPU and thus will be excluded from the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Vancouver General Hospital Vancouver British Columbia Canada V5Z 1M9

    Sponsors and Collaborators

    • University of British Columbia

    Investigators

    • Principal Investigator: Prisman Eitan, MD, FRCSC, University of British Columbia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Eitan Prisman, Principal Investigator, University of British Columbia
    ClinicalTrials.gov Identifier:
    NCT03171558
    Other Study ID Numbers:
    • H14-00004
    First Posted:
    May 31, 2017
    Last Update Posted:
    May 31, 2017
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 31, 2017